선택적 제품 분석
허용하는 경우 개인정보 보호를 고려한 제한적 분석을 사용해 어떤 리서치 여정이 효과적인지 파악합니다. 광고 추적기나 세션 녹화는 사용하지 않습니다. 환경설정에서 이 선택을 변경할 수 있습니다. 자세한 내용은 개인정보 처리방침.
Healthpeak Properties, Inc.'s published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $14.4B | |
|---|---|---|
| Revenue (ttm) | 2.9B | |
| Net income (ttm) | 242.7M | |
| EPS (ttm) | $0.34 | |
| Shares out | 702.5M | |
| P/E (trailing) | 53.8x | |
| P/E (forward) | 169.5x | |
| Dividend | $1.22 (6.61%) | |
| Volume | 3,305,847 | |
| Beta | 0.99 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $471.3M | $494.9M | $527.4M | $568.5M | $604.0M | +6.4% |
| Gross profit | $1.12B | $1.20B | $1.28B | $1.63B | $634.5M | -13.3% |
| Operating income | $286.3M | $680.1M | $515.3M | $553.6M | $415.5M | +9.8% |
| Net income | $505.5M | $500.4M | $306.0M | $243.1M | $71.3M | -38.7% |
| EPS (diluted) | $0.93 | $0.92 | $0.56 | $0.36 | $0.10 | -42.7% |
| EBITDA | $970.6M | $1.39B | $1.27B | $1.61B | $1.47B | +11.0% |
| R&D | $0 | $0 | $0 | — | — | +41.4% |
| SG&A | $98.3M | $131.0M | $95.1M | $97.2M | $90.4M | -2.1% |
Recent company headlines from major financial publishers.
Defensive outpatient medical cash flows deliver steady collections, balancing lab leasing drag and debt service to yield $29.98 from $20.33.
Post-merger integration accelerates synergies, outpatient rent escalations exceed historical norms, and life science leasing spreads rebound, supporting $40.86.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 6.4% | $78.0 | $78.3 | $78.8 | $79.4 | $80.2 |
| 7.4% | $42.6 | $42.8 | $43.1 | $43.5 | $43.9 |
| 8.4% | $29.6 | $29.8 | $30.0 | $30.2 | $30.5 |
| 9.4% | $22.8 | $23.0 | $23.1 | $23.3 | $23.4 |
| 10.4% | $18.6 | $18.7 | $18.8 | $18.9 | $19.1 |
Upcoming earnings date and setup when available.
매월 발행된 리서치 판이 부여한 등급입니다. 등급은 분석 시점의 가격을 공정 가치와 비교한 것이며, 판단이 맞았는지에 대한 기록이 아닙니다.
| 연도 | 1월 | 2월 | 3월 | 4월 | 5월 | 6월 | 7월 | 8월 | 9월 | 10월 | 11월 | 12월 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |